Unknown

Dataset Information

0

Metformin is associated with reduced COVID-19 severity in patients with prediabetes.


ABSTRACT:

Aims

Studies suggest that metformin is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemics. We assessed if metformin is associated with reduced incidence of severe COVID-19 for patients with prediabetes or polycystic ovary syndrome (PCOS), common diseases that increase the risk of severe COVID-19.

Methods

This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls). After balancing via inverse probability score weighting, associations with COVID-19 severity were assessed by logistic regression.

Results

In the prediabetes cohort, when compared to levothyroxine, metformin was associated with a significantly lower incidence of COVID-19 with "mild-ED" or worse (OR [95% CI]: 0.636, [0.455-0.888]) and "moderate" or worse severity (0.493 [0.339-0.718]). Compared to ondansetron, metformin was associated with lower incidence of "mild-ED" or worse severity (0.039 [0.026-0.057]), "moderate" or worse (0.045 [0.03-0.069]), "severe" or worse (0.183 [0.077-0.431]), and "mortality/hospice" (0.223 [0.071-0.694]). For PCOS, metformin showed no significant differences in severity compared to levothyroxine, but was associated with a significantly lower incidence of "mild-ED" or worse (0.101 [0.061-0.166]), and "moderate" or worse (0.094 [0.049-0.18]) COVID-19 outcome compared to ondansetron.

Conclusions

Metformin use is associated with less severe COVID-19 in patients with prediabetes or PCOS.

SUBMITTER: Chan LE 

PROVIDER: S-EPMC9663381 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Aims</h4>Studies suggest that metformin is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemics. We assessed if metformin is associated with reduced incidence of severe COVID-19 for patients with prediabetes or polycystic ovary syndrome (PCOS), common diseases that increase the risk of severe COVID-19.<h4>Methods</h4>This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes  ...[more]

Similar Datasets

| S-EPMC9460973 | biostudies-literature
| S-EPMC8013587 | biostudies-literature
2022-05-03 | GSE201790 | GEO
2021-07-07 | GSE161810 | GEO
2022-07-19 | E-MTAB-10926 | biostudies-arrayexpress
2022-08-28 | GSE212041 | GEO
| S-EPMC9650570 | biostudies-literature
2023-07-19 | GSE236017 | GEO
| S-EPMC7832745 | biostudies-literature
2022-03-01 | E-MTAB-10970 | biostudies-arrayexpress